The Food and Drug Administration in December approved the use of Apretude, the first long-acting injectable option to prevent HIV infection — a decision that will be a game-changer in the fight against the epidemic.
While Gilead’s Truvada pill has been approved for use as pre-exposure prophylaxis, or PrEP, since 2012 — and, when taken daily, lowers users’ risks from contracting HIV through sex by about 99 percent — taking the medication without fail has proven